Trisomy 13
12
0
0
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
8.3%
1 terminated out of 12 trials
90.9%
+4.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (12)
Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies
Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial
VAlidation of a Lower Cost aneUploidy scrEen
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood
Non-Invasive Chromosomal Evaluation of Trisomy Study
Multiple Gestation Study
Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA
High Risk Multiple Gestation Study
Study of Vanadis® NIPT for Non-invasive Prenatal Screening of Trisomies (T21, T18 and T13)
Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood
Prenatal Screening for Down Syndrome With DNAFirst